Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis

被引:0
|
作者
Naves, Marcio Coutinho Xavier [1 ]
Amato, Angelica Amorim [2 ]
Zimmermann, Ivan Ricardo [3 ,4 ]
Peixoto, Henry Maia [4 ,5 ]
机构
[1] Univ Brasilia, Sch Hlth Sci, Brasilia, Brazil
[2] Univ Brasilia, Lab Mol Pharmacol, Brasilia, Brazil
[3] Univ Brasilia, Dept Publ Hlth, Brasilia, Brazil
[4] Natl Inst Sci & Technol Hlth Technol Assessment, Porto Alegre, Brazil
[5] Univ Brasilia, Ctr Trop Med, Brasilia, Brazil
来源
关键词
Heart failure; Dapagliflozin; Cost-effectiveness; QALY; Brazil; HEALTH OUTCOMES; BURDEN; CARE; PATTERNS; TRENDS;
D O I
10.1016/j.lana.2024.100968
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Heart failure, a complex clinical syndrome with high morbidity and mortality, has become a significant burden on public health. Recently, a new class of antidiabetic agents-the sodium-glucose cotransporter 2 (SGLT2) inhibitors-was associated with a significant reduction on mortality and hospitalization in HF with reduced ejection fraction (HFrEF) when added to standard pharmacological treatment. Considering the lack of data on its cost-effectiveness, the present study aims to estimate the incremental cost-effectiveness ratio of add-on dapagliflozin treatment for HFrEF from the Brazilian public healthcare system perspective. Methods We built a Markov model to estimate the clinical outcomes and costs of 1,000 hypothetical subjects with established HFrEF in a lifetime horizon. The model inputs were based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial and local data. The main outcome was the incremental costeffectiveness ratio (ICER) per quality-adjusted life year (QALY) gained. Deterministic and probabilistic sensitivity analyses, as well as scenario analyses, were performed. Findings The addition of dapagliflozin to standard care treatment in 1,000 HFrEF patients yielded an expected value of 366.99 additional QALYs at an incremental cost of US$ 1,517,878.49, resulting in an ICER of US$ 4,136.08 per QALY gained, being a cost-effective strategy considering the Brazilian official cost-effectiveness threshold (US$ 8,000/ QALY). In probabilistic sensitivity analyses, 96.60% of the simulations were also cost-effective. In the scenario analyses, results were similar for individuals with and without diabetes. Interpretation Dapagliflozin is likely to be cost-effective when added to standard HFrEF therapy in Brazil. Funding This study was supported by the National Institute of Science and Technology for Health Technology Assessment (Instituto de Avalia & ccedil;& atilde;o de Tecnologias em Sa & uacute;de-IATS).
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [2] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    CIRCULATION, 2020, 142
  • [3] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [4] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [5] COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS
    Cavusoglu, Y.
    Demir, O.
    Dinc, M.
    Ozsoy, A.
    Erdogan, A.
    Ozer, S.
    VALUE IN HEALTH, 2022, 25 (01) : S66 - S66
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [7] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [8] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [9] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Ghader Mohammadnezhad
    Behniya Azadmehr
    Mehdi Mirheidari
    Nazila Yousefi
    Cost Effectiveness and Resource Allocation, 20
  • [10] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Mohammadnezhad, Ghader
    Azadmehr, Behniya
    Mirheidari, Mehdi
    Yousefi, Nazila
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)